Kebede Hussein

1.1k citations

20 papers · 709 indexed · h-index 11

Co-authors: Ayalew Tefferi Animesh Pardanani Daniel L. Van Dyke Curtis A. Hanson Susan M. Schwager Ruben A. Mesa Ruth Coxon David G. Lalloo
Topics: Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers)Acute Myeloid Leukemia Research (9 papers)Chronic Myeloid Leukemia Treatments (9 papers)
Cited by: Genetics Hematology Rheumatology
Journals: New England Journal of Medicine Blood Mayo Clinic Proceedings
Partner nations: United States Italy United Kingdom

In The Last Decade

Kebede Hussein

20 papers receiving 696 citations

Peers

Countries citing papers authored by Kebede Hussein

Since Specialization

Citations

This map shows the geographic impact of Kebede Hussein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kebede Hussein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kebede Hussein more than expected).

Fields of papers citing papers by Kebede Hussein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kebede Hussein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kebede Hussein. The network helps show where Kebede Hussein may publish in the future.

Co-authorship network of co-authors of Kebede Hussein

This figure shows the co-authorship network connecting the top 25 collaborators of Kebede Hussein. A scholar is included among the top collaborators of Kebede Hussein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kebede Hussein. Kebede Hussein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype 2009 ·American Journal of Hematology ·Ayalew Tefferi,Sergio Siragusa,Kebede Hussein,Susan M. Schwager,Curtis A. Hanson,Animesh Pardanani,Francisco Cervantes,Francesco Passamonti	52
2	Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype–phenotype associations 2009 ·European Journal Of Haematology ·Domenica Caramazza,Kebede Hussein,Sergio Siragusa,Animesh Pardanani,Ryan A. Knudson,Rhett P. Ketterling,Ayalew Tefferi	18
3	Conventional cytogenetics in myelofibrosis: literature review and discussion 2009 ·European Journal Of Haematology ·Kebede Hussein,Daniel L. Van Dyke,Ayalew Tefferi	67
4	Mature Survival Data for 176 Patients Younger Than 60 Years With Primary Myelofibrosis Diagnosed Between 1976 and 2005: Evidence for Survival Gains in Recent Years 2009 ·Mayo Clinic Proceedings ·Rakhee Vaidya,Sergio Siragusa,Jocelin Huang,Susan M. Schwager,Curtis A. Hanson,Kebede Hussein,Animesh Pardanani,Ayalew Tefferi	11
5	Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not 2009 ·American Journal of Hematology ·Ayalew Tefferi,Ruben A. Mesa,Animesh Pardanani,Kebede Hussein,Susan M. Schwager,Curtis A. Hanson,David P. Steensma	35
6	IPSS-Independent Cytogenetic Risk Categorization in Primary Myelofibrosis. 2009 ·Blood ·Kebede Hussein,Animesh Pardanani,Daniel Van Dyke,Curtis A. Hanson,Ayalew Tefferi	1
7	The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis 2009 ·Leukemia Research ·Ruben A. Mesa,Susan M. Schwager,Deepti Radia,Andrea Cheville,Kebede Hussein,Joyce Niblack,Animesh Pardanani,David P. Steensma,Mark R. Litzow,Candido E. Rivera,John Camoriano,Srđan Verstovšek,Jeffrey A. Sloan,Claire Harrison,Hagop M. Kantarjian,Ayalew Tefferi	168
8	Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis. 2009 ·Blood ·Ruben A. Mesa,Animesh Pardanani,Kebede Hussein,Wenting Wu,Susan M. Schwager,Mark R. Litzow,William J. Hogan,Ayalew Tefferi	3
9	A JAK2 Germline Genetic Variation Is Associated with Shortened Survival in Primary Myelofibrosis: Clinical and JAK2V617F Allele Burden Correlates of rs12343867 SNP Genotype in 132 Cases. 2009 ·Blood ·Ayalew Tefferi,Terra L. Lasho,Christy M. Finke,Kebede Hussein,Michelle A. Elliott,Animesh Pardanani	1
10	Weight Loss, Splenomegaly, and Hypocholesterolemia in Myeloproliferative Neoplasms: Patterns and Relevance from the Pre JAK2 Inhibitor Era. 2009 ·Blood ·Ruben A. Mesa,Susan M. Schwager,Jocelin Huang,Animesh Pardanani,Kebede Hussein,John Camoriano,Ayalew Tefferi	10
11	International Prognostic Scoring System–independent cytogenetic risk categorization in primary myelofibrosis 2009 ·Blood ·Kebede Hussein,Animesh Pardanani,Daniel L. Van Dyke,Curtis A. Hanson,Ayalew Tefferi	81
12	Karyotype complements the International Prognostic Scoring System for primary myelofibrosis 2009 ·European Journal Of Haematology ·Kebede Hussein,Jocelin Huang,Terra L. Lasho,Animesh Pardanani,Ruben A. Mesa,(unknown),Rhett P. Ketterling,Curtis A. Hanson,Daniel L. Van Dyke,Ayalew Tefferi	34
13	Peripheral blood cytogenetic studies in myelofibrosis: Overall yield and comparison with bone marrow cytogenetic studies 2008 ·Leukemia Research ·Kebede Hussein,Rhett P. Ketterling,Gordon W. Dewald,Daniel L. Van Dyke,Ruben A. Mesa,Curtis A. Hanson,Ayalew Tefferi	4
14	JAK2V617F Mutation Screening as Part of the Hypercoagulable Work-up in the Absence of Splanchnic Venous Thrombosis or Overt Myeloproliferative Neoplasm: Assessment of Value in a Series of 664 Consecutive Patients 2008 ·Mayo Clinic Proceedings ·Animesh Pardanani,Terra L. Lasho,Kebede Hussein,Susan M. Schwager,(unknown),Rajiv K. Pruthi,Ayalew Tefferi	33
15	Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia 2008 ·American Journal of Hematology ·Kebede Hussein,Balkrishna Jahagirdar,Pankaj Gupta,Linda J. Burns,Karen Larsen,Daniel J. Weisdorf	41
16	Dynamics, and Prognostic Impact, of Weight Loss in Primary Myelofibrosis 2008 ·Blood ·Ruben A. Mesa,Susan M. Schwager,Jocelin Huang,Kebede Hussein,Animesh Pardanani,Ayalew Tefferi	4
17	Assessment and Monitoring of Constitutional Symptoms in Patients with Myelofibrosis: A Proposed New Instrument the Myelofibrosis Symptom Assessment Form (MFSAF). 2008 ·Blood ·Ruben A. Mesa,Susan M. Schwager,Deepti Radia,Andrea Cheville,Kebede Hussein,Joyce Niblack,Animesh Pardanani,David P. Steensma,Mark R. Litzow,Candido E. Rivera,John Camoriano,Srđan Verstovšek,Jeffrey A. Sloan,Claire Harrison,Ayalew Tefferi	3
18	Peripheral blood cytogenetic studies in hematological neoplasms: predictors of obtaining metaphases for analysis 2007 ·European Journal Of Haematology ·Kebede Hussein,Rhett P. Ketterling,(unknown),(unknown),Anne E. Wiktor,Curtis A. Hanson,Ayalew Tefferi,Daniel L. Van Dyke	8
19	Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative Patients. 2007 ·Blood ·Ruben A. Mesa,Jocelin Huang,Susan M. Schwager,Animesh Pardanani,Kebede Hussein,David Dingli,Michael J. Jensen,(unknown),Ayalew Tefferi	8
20	Prevention of Jarisch–Herxheimer Reactions by Treatment with Antibodies against Tumor Necrosis Factor α 1996 ·New England Journal of Medicine ·Daniel Fekade,Kyle Knox,Kebede Hussein,(unknown),David G. Lalloo,Ruth Coxon,(unknown)	127

About Kebede Hussein

Kebede Hussein is a scholar working on Genetics, Hematology and Rheumatology, having authored 20 papers that have together received 709 indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (19 papers), Acute Myeloid Leukemia Research (9 papers) and Chronic Myeloid Leukemia Treatments (9 papers). The work is most often cited by research in Genetics (513 citations), Hematology (451 citations) and Rheumatology (192 citations). Kebede Hussein has collaborated with scholars based in United States, Italy and United Kingdom. Frequent co-authors include Ayalew Tefferi, Animesh Pardanani, Daniel L. Van Dyke, Curtis A. Hanson, Susan M. Schwager, Ruben A. Mesa, Ruth Coxon, David G. Lalloo, Kyle Knox and Daniel Fekade. Their work appears in journals such as New England Journal of Medicine, Blood and Mayo Clinic Proceedings.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact